Abstract
Patricio Favier, Pedro Suárez-Urquiza, Carla Lorena Raffo, Diego Torres, Fidel Pinilla-Huayta, Claudia Muñoz-Soto, Matías Ravelli, Enrique Serio, Liliana Kumar, Pérez Johanna, Ivana Primost, María Inés Gallino, Javier Pemán, Amparo Valentín-Martín, Eva María Gonzalez‐Barberá
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Update on the epidemiology of carbapenemases in Latin America and the Caribbean
10.1080/14787210.2020.1813023 · 2021
A Seven-Year Microbiological and Molecular Study of Bacteremias Due to Carbapenemase-Producing Klebsiella pneumoniae: An Interrupted Time-Series Analysis of Changes in the Carbapenemase Gene’s Distribution after Introduction of Ceftazidime/Avibactam
10.3390/antibiotics11101414 · 2022
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam
10.1093/jac/dkz125 · 2019
Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017–2019
10.1016/j.jfma.2021.04.014 · 2021
Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae
10.1128/aac.02373-13 · 2014
Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes
10.1016/j.diagmicrobio.2010.02.001 · 2010
Risks of Infection and Mortality Among Patients Colonized with Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Validation of Scores and Proposal for Management
10.1093/cid/cix991 · 2018
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales
10.1128/aac.01676-21 · 2022
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
10.1016/j.cmi.2021.11.025 · 2022
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment
10.1111/j.1469-0691.2011.03514.x · 2011
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: Can we apply “precision medicine” to antimicrobial chemotherapy?
10.1517/14656566.2016.1145658 · 2016
Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
10.1016/j.ijid.2017.03.021 · 2017
Change in Klebsiella pneumoniae susceptibility profile after the arrival of ceftazidime-avibactam in an Argentinean intensive care unit: a new ecological landscape
10.37201/req/042.2024 · 2024
Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study
10.1111/1469-0691.12747 · 2014
Evaluación del Gianella Risk Score en pacientes adultos con colonización rectal por Klebsiella pneumoniae productora de carbapenemasas en el Hospital General del Norte de Guayaquil Los Ceibos, durante el periodo de enero 2018 a junio 2019
10.46721/tejom-vol3iss1-2021-30-45 · 2021
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
10.1016/s1473-3099(17)30228-1 · 2017
Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: Who is prone to become clinically infected?
10.1111/j.1469-0691.2012.03888.x · 2013
Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae
10.1016/j.ajic.2011.05.022 · 2012
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
10.1093/cid/cis588 · 2012
Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
10.1111/j.1469-0691.2011.03478.x · 2012
Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems
10.1128/aac.00406-17 · 2017
A Predictive Model of Mortality in Patients with Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
10.1016/j.mayocp.2016.06.024 · 2016
The Global Burden of Sepsis and Septic Shock
10.3390/epidemiologia5030032 · 2024
Unresolved referenced work
2017
Klebsiella pneumoniae Carbapenemase–2, Buenos Aires, Argentina
10.3201/eid1407.070826 · 2008
Unresolved referenced work
2019
The post-antibiotic era has arrived: interventions to contain an outbreak of pan-drug-resistant (PDR) NDM-1 and OXA-48-like dual-producer Providencia stuartii in an acute care hospital in Argentina
2017
Emergence of NDM-1-producing Klebsiella pneumoniae in Guatemala
10.1093/jac/dks101 · 2012
Evaluation of the Blue-Carba Test for Rapid Detection of Carbapenemases in Gram-Negative Bacilli
10.1128/jcm.03026-14 · 2015
Unresolved referenced work
2019
No additional external references are available.